SetPoint Medical: A Bioelectronic Therapy for the Largest Drug Market

article image

SetPoint Medical has developed a bioelectronic medicine to treat chronic inflammation-mediated diseases of the immune system, such as rheumatoid arthritis and Crohn’s disease. Unlike neuromodulation therapies that have come before, SetPoint elicits a molecular, rather than functional, reaction from the body, restoring the regulatory signal that tells the body to downregulate pro-inflammatory cytokines.

In the recent investor presentations of major medical device companies, neuromodulation has been cast as a platform for growth into billion-dollar-plus markets currently dominated by pharmaceutical treatments.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite


We're here to help! Please contact us at: